Literature DB >> 1675689

Pharmacologic aspects of benzodiazepine tolerance and dependence.

U Busto1, E M Sellers.   

Abstract

Benzodiazepines, which are among the safest and most effective drugs, possess all the characteristic of abuseable compounds. Although there appear to be differences in potency among compounds and variations in sensitivity among individuals, benzodiazepines have clear reinforcing properties. Tolerance to the depressant effects of benzodiazepines is rapid, but tolerance to the anxiolytic effects develops slowly and to a limited extent. Although abusers use very high doses, most long-term users persist at daily doses in the low therapeutic range (10-20 mg of diazepam or its equivalent) without dose escalation. Physical dependence is a risk associated with long-term use, even at therapeutic doses. The withdrawal syndrome is mild at low doses. Continued self-administration of low therapeutic doses is maintained to alleviate withdrawal symptoms. The advances in the recent understanding of the molecular biology of the benzodiazepine receptor gives hope to the development of new anxiolytic compounds with less dependence liability than the present ones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675689     DOI: 10.1016/0740-5472(91)90024-5

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  6 in total

1.  Benzodiazepines: more "behavioural" addiction than dependence.

Authors:  Carlos de las Cuevas; Emilio Sanz; Juan de la Fuente
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

2.  Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam.

Authors:  J J Byrnes; L G Miller; D J Greenblatt; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances.

Authors:  Julien Cases; Alvin Ibarra; Nicolas Feuillère; Marc Roller; Samir G Sukkar
Journal:  Med J Nutrition Metab       Date:  2010-12-17

4.  Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study.

Authors:  Yuichi Inoue; Yoshikazu Takaesu; Michinori Koebis
Journal:  BMC Psychiatry       Date:  2021-04-14       Impact factor: 3.630

5.  Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?

Authors:  Alexander Gallo; Tim MacDonald; Kellie Bennett; Gioiamia Basso-Hulse; Gary Hulse
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

6.  Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland.

Authors:  K O'Sullivan; U Reulbach; F Boland; N Motterlini; D Kelly; K Bennett; T Fahey
Journal:  BMJ Open       Date:  2015-06-09       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.